FDA Commissioner Hahn’s Priorities Include Workplace Development Issues, Data Collection
Among Stephen Hahn’s priorities and long-term ambitions for his time at the US agency are retaining and recruiting the best possible professional staff, and collection and use of data, regulatory consultants and attorneys say.
You may also be interested in...
In an all-hands email to US FDA staff on 30 January, the new commissioner outlined his top priorities for the agency, including focusing on data when reviewing medical products, getting more feedback from patients and consumers, and finding ways to make the agency more efficient.
Hahn Fields Queries On Electrical Stim Devices, Molybdenum Supplies For Imaging At FDA Confirmation Hearing
MD Anderson Cancer Center chief medical officer Stephen Hahn fielded a number of questions senators asked at his 20 November confirmation hearing to lead the US FDA. Chief among them were inquiries about his government experience level, whether he would expedite a ban on electrical stimulation devices used against the intellectually disabled, and how he would address a shortage of molybdenum-99 used in advanced imaging scans.
Acting US FDA Commissioner Ned Sharpless described his vision for an efficient, adaptable agency on 2 May at the Food & Drug Law Institute’s annual conference in Washington, DC.